Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Booz Allen Hamilton Holding Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Booz Allen Hamilton Holding Corporation trades at $78.74 (market cap $9.45B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.1× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BAH | |
|---|---|---|
Market Cap | $29.60B | $9.45B |
Sector | Health | Industrials |
52-Week High | $491.22 | $111.63 |
52-Week Low | $205.48 | $59.71 |
Enterprise Value | $27.56B | $13.07B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Booz Allen Hamilton (BAH) trades at $78.4, up 0.64% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 68.11% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights its focus on AI and cybersecurity, with a consensus analyst price target of $84.67 suggesting upside potential. Cash flow from operations improved to $1.01 billion in 2025.
The outlook is supported by national security demand and margin expansion, but risks include civil revenue weakness and high leverage. Valuation appears reasonable with a P/E of 12.33. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock offers a dividend yield from recent payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
